Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Classifica tra le azioni #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Prezzo delle azioni
$193.62
Capitalizzazione di mercato
$150.08B
Variazione (1 giorno)
2.76%
Variazione (1 anno)
184.69%
Paese
GB
Scambia AstraZeneca PLC (AZN)

Categoria

Ricavi di AstraZeneca PLC (AZN)
Ricavi nel Dec 2025 TTM: $58.74B
Secondo gli ultimi rapporti finanziari di AstraZeneca PLC, i ricavi attuali dell'azienda (TTM) sono pari a $58.74B. Nel 2024, l'azienda ha registrato ricavi di $54.07B un aumento rispetto a i ricavi dell'anno 2023, che erano pari a $45.81B. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per AstraZeneca PLC da 2000 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $58.74B 0.00%
2025 $58.74B 8.63%
2024 $54.07B 18.03%
2023 $45.81B 3.29%
2022 $44.35B 18.53%
2021 $37.42B 40.58%
2020 $26.62B 9.16%
2019 $24.38B 10.38%
2018 $22.09B -1.67%
2017 $22.47B -2.33%
2016 $23.00B -6.90%
2015 $24.71B -6.93%
2014 $26.55B 2.87%
2013 $25.81B -7.75%
2012 $27.97B -16.72%
2011 $33.59B 0.97%
2010 $33.27B 1.42%
2009 $32.80B 3.81%
2008 $31.60B 6.91%
2007 $29.56B 11.65%
2006 $26.48B 10.54%
2005 $23.95B 11.78%
2004 $21.43B 13.67%
2003 $18.85B 5.65%
2002 $17.84B 8.26%
2001 $16.48B -9.03%
2000 $18.12B 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
$65.18B 10.96%
US
$94.19B 60.36%
US
$61.16B 4.12%
US
$56.15B -4.41%
CH
$65.01B 10.68%
US